Press release
June 30, 2026
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
HCW Biologics Inc. (HCWB)
Company now compliant with all continued listing rules for Nasdaq MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to